217 related articles for article (PubMed ID: 9512184)
1. Use of a microquantity enzyme immunoassay in a large-scale study of measles, mumps and rubella immunity in Italy.
Condorelli F; Stivala A; Gallo R; Marino A; Battaglini CM; Messina A; Russo G; Castro A; Scalia G
Eur J Clin Microbiol Infect Dis; 1998 Jan; 17(1):49-52. PubMed ID: 9512184
[TBL] [Abstract][Full Text] [Related]
2. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
Matter L; Germann D; Bally F; Schopfer K
Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
[TBL] [Abstract][Full Text] [Related]
3. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
[TBL] [Abstract][Full Text] [Related]
4. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
5. Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy.
Madi N; Altawalah H; Alfouzan W; Al-Nakib W; Al-Roumi E; Jeragh A
J Med Virol; 2020 Aug; 92(8):963-970. PubMed ID: 31919861
[TBL] [Abstract][Full Text] [Related]
6. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
[TBL] [Abstract][Full Text] [Related]
7. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.
Wang Z; Yan R; He H; Li Q; Chen G; Yang S; Chen E
PLoS One; 2014; 9(2):e89361. PubMed ID: 24586717
[TBL] [Abstract][Full Text] [Related]
8. Decay of passively acquired maternal antibodies against measles, mumps, and rubella viruses.
Nicoara C; Zäch K; Trachsel D; Germann D; Matter L
Clin Diagn Lab Immunol; 1999 Nov; 6(6):868-71. PubMed ID: 10548578
[TBL] [Abstract][Full Text] [Related]
9. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
Tischer A; Gerike E
Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
[TBL] [Abstract][Full Text] [Related]
10. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
[TBL] [Abstract][Full Text] [Related]
11. Measles, Mumps, and Rubella Serostatus and Response to MMR Vaccination Among HIV-Infected Adults.
Singh HK; Chiu YL; Wilkin T
AIDS Patient Care STDS; 2015 Sep; 29(9):461-4. PubMed ID: 26153909
[No Abstract] [Full Text] [Related]
12. Prevalence of antibodies against measles, mumps and rubella in the childhood population in Singapore, 2008-2010.
Ang LW; Lai FY; Tey SH; Cutter J; James L; Goh KT
Epidemiol Infect; 2013 Aug; 141(8):1721-30. PubMed ID: 22999024
[TBL] [Abstract][Full Text] [Related]
13. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G
Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870
[TBL] [Abstract][Full Text] [Related]
14. Seroprevalence of measles, mumps and rubella antibodies in Luxembourg: results from a national cross-sectional study.
Mossong J; Putz L; Schneider F
Epidemiol Infect; 2004 Jan; 132(1):11-8. PubMed ID: 14979584
[TBL] [Abstract][Full Text] [Related]
15. Seroprevalence of measles, mumps, rubella, and varicella zoster virus antibodies among healthcare students: analysis of vaccine efficacy and cost-effectiveness.
Ödemiş Í; Köse Ş; Akbulut Í; Albayrak H
Rev Esp Quimioter; 2019 Dec; 32(6):525-531. PubMed ID: 31642641
[TBL] [Abstract][Full Text] [Related]
16. Seroprevalence of antibodies to measles, mumps, and rubella among Thai population: evaluation of measles/MMR immunization programme.
Tharmaphornpilas P; Yoocharean P; Rasdjarmrearnsook AO; Theamboonlers A; Poovorawan Y
J Health Popul Nutr; 2009 Feb; 27(1):80-6. PubMed ID: 19248651
[TBL] [Abstract][Full Text] [Related]
17. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines.
Crovari P; Gabutti G; Giammanco G; Dentico P; Moiraghi AR; Ponzio F; Soncini R
Vaccine; 2000 Jun; 18(25):2796-803. PubMed ID: 10812221
[TBL] [Abstract][Full Text] [Related]
18. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
[TBL] [Abstract][Full Text] [Related]
19. Seroprevalence of measles, mumps & rubella antibodies among 5-10 years old children in north India.
Gupta M; Tripathy JP; Verma M; Singh MP; Kaur R; Ratho RK; Kumar R
Indian J Med Res; 2019 Mar; 149(3):396-403. PubMed ID: 31249206
[TBL] [Abstract][Full Text] [Related]
20. The Immunogenicity and Safety Profile for KM-248, a Combined Measles, Mumps, and Rubella Vaccine, and Its Noninferiority to the Measles Vaccine in Healthy Japanese Children: a Phase 3 Randomized Multicenter Single-Blind Clinical Trial.
Platt H; Tochihara S; Oda Y; Ueda K
Jpn J Infect Dis; 2021 Sep; 74(5):429-436. PubMed ID: 33518626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]